STAT protein family and cardiovascular diseases: overview of pathological mechanisms and therapeutic implications.
Cardiovascular diseases
Pathological mechanisms
STAT family proteins
Journal
Molecular biology reports
ISSN: 1573-4978
Titre abrégé: Mol Biol Rep
Pays: Netherlands
ID NLM: 0403234
Informations de publication
Date de publication:
23 Mar 2024
23 Mar 2024
Historique:
received:
11
09
2023
accepted:
21
02
2024
medline:
23
3
2024
pubmed:
23
3
2024
entrez:
23
3
2024
Statut:
epublish
Résumé
Globally, cardiovascular diseases (CVD) are one of the significant causes of death and are considered a major concern of human society. One of the most crucial objectives of scientists is to reveal the mechanisms associated with the pathogenesis of CVD, which has attracted the attention of many scientists. Accumulating evidence showed that the signal transducer and activator of transcription (STAT) signaling pathway is involved in various physiological and pathological processes. According to research on the molecular mechanisms of CVDs, the STAT family of proteins is one of the most crucial players in these diseases. Numerous studies have demonstrated the undeniable relevance of STAT family proteins in various CVDs. The aim of this review is to shed light on how STAT signaling pathways are related to CVD and the potential for using these signaling pathways as therapeutic targets.
Identifiants
pubmed: 38520542
doi: 10.1007/s11033-024-09371-2
pii: 10.1007/s11033-024-09371-2
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
440Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Harhous Z, Booz GW, Ovize M, Bidaux G, Kurdi M (2019) An update on the multifaceted roles of STAT3 in the heart. Front Cardiovasc Med. 6
Şahin B, İlgün G (2022) Risk factors of deaths related to cardiovascular diseases in World Health Organization (WHO) member countries. Health Soc Care Commun 30(1):73–80
doi: 10.1111/hsc.13156
Kishore R, Verma SK (2012) Roles of STATs signaling in cardiovascular diseases. Jak-stat 1(2):118–124
pubmed: 24058760
doi: 10.4161/jkst.20115
Verhoeven Y, Tilborghs S, Jacobs J, De Waele J, Quatannens D, Deben C et al (eds) (2020) The potential and controversy of targeting STAT family members in cancer. Seminars in cancer biology. Elsevier
Hu X, li J, Fu M, Zhao X, Wang W (2021) The JAK/STAT signaling pathway: from bench to clinic. Signal Transduct Target Therapy 6(1):402
doi: 10.1038/s41392-021-00791-1
Mao X, Ren Z, Parker GN, Sondermann H, Pastorello MA, Wang W et al (2005) Structural bases of unphosphorylated STAT1 association and receptor binding. Mol Cell 17(6):761–771
pubmed: 15780933
doi: 10.1016/j.molcel.2005.02.021
Ebersbach C, Beier A-MK, Thomas C, Erb HH (2021) Impact of STAT proteins in Tumor Progress and Therapy Resistance in Advanced and metastasized prostate Cancer. Cancers 13(19):4854
pubmed: 34638338
doi: 10.3390/cancers13194854
Verhoeven Y, Tilborghs S, Jacobs J, De Waele J, Quatannens D, Deben C et al (2020) The potential and controversy of targeting STAT family members in cancer. Semin Cancer Biol 60:41–56
pubmed: 31605750
doi: 10.1016/j.semcancer.2019.10.002
Levy DE, Darnell JE (2002) STATs: transcriptional control and biological impact. Nat Rev Mol Cell Biol 3(9):651–662
pubmed: 12209125
doi: 10.1038/nrm909
Ebersbach C, Beier AK, Thomas C, Erb HHH (2021) Impact of STAT proteins in Tumor Progress and Therapy Resistance in Advanced and Metastasized. Prostate Cancer 13:19
Konjević G, Radenković S, Vuletić A, Martinović KM, Jurišić V, Srdic T (2013) STAT transcription factors in tumor development and targeted therapy of malignancies. IntechOpen, Oncogene and Cancer-From Bench to Clinic
doi: 10.5772/54893
Takeda K, Akira S (2000) STAT family of transcription factors in cytokine-mediated biological responses. Cytokine Growth Factor Rev 11(3):199–207
pubmed: 10817963
doi: 10.1016/S1359-6101(00)00005-8
Furqan M, Akinleye A, Mukhi N, Mittal V, Chen Y, Liu D (2013) STAT inhibitors for cancer therapy. J Hematol Oncol 6(1):90
pubmed: 24308725
doi: 10.1186/1756-8722-6-90
Seif F, Khoshmirsafa M, Aazami H, Mohsenzadegan M, Sedighi G, Bahar M (2017) The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells. Cell Communication Signal 15(1):23
doi: 10.1186/s12964-017-0177-y
Saadatian Z, Nariman-Saleh-Fam Z, Bastami M, Mansoori Y, Khaheshi I, Parsa SA et al (2019) Dysregulated expression of STAT1, miR-150, and miR-223 in peripheral blood mononuclear cells of coronary artery disease patients with significant or insignificant stenosis. J Cell Biochem 120(12):19810–19824
pubmed: 31318097
doi: 10.1002/jcb.29286
Sikorski K, Czerwoniec A, Bujnicki JM, Wesoly J, Bluyssen HA (2011) STAT1 as a novel therapeutical target in pro-atherogenic signal integration of IFNγ, TLR4 and IL-6 in vascular disease. Cytokine Growth Factor Rev 22(4):211–219
pubmed: 21752694
doi: 10.1016/j.cytogfr.2011.06.003
Chmielewski S, Olejnik A, Sikorski K, Pelisek J, Błaszczyk K, Aoqui C et al (2014) STAT1-dependent signal integration between IFNγ and TLR4 in vascular cells reflect pro-atherogenic responses in human atherosclerosis. PLoS ONE 9(12):e113318
pubmed: 25478796
doi: 10.1371/journal.pone.0113318
Zhu L, Wang F, Yang H, Zhang J, Chen S (2020) Low shear stress damages endothelial function through STAT1 in endothelial cells (ECs). J Physiol Biochem 76(1):147–157
pubmed: 32037480
doi: 10.1007/s13105-020-00729-1
Liu S, He Y, Shi J, Liu L, Ma H, He L et al (2019) STAT1-avtiviated LINC00961 regulates myocardial infarction by the PI3K/AKT/GSK3β signaling pathway. J Cell Biochem 120(8):13226–13236
pubmed: 30887575
doi: 10.1002/jcb.28596
McCormick J, Suleman N, Scarabelli TM, Knight RA, Latchman DS, Stephanou A (2012) STAT1 deficiency in the heart protects against myocardial infarction by enhancing autophagy. J Cell Mol Med 16(2):386–393
pubmed: 21447043
doi: 10.1111/j.1582-4934.2011.01323.x
McCormick J, Barry SP, Sivarajah A, Stefanutti G, Townsend PA, Lawrence KM et al (2006) Free radical scavenging inhibits STAT phosphorylation following in vivo ischemia/reperfusion injury. FASEB J 20(12):2115–2117
pubmed: 16935931
doi: 10.1096/fj.06-6188fje
Bourke LT, Knight RA, Latchman DS, Stephanou A, McCormick J (2013) Signal transducer and activator of transcription-1 localizes to the mitochondria and modulates mitophagy. Jak-stat 2(4):e25666
pubmed: 24470977
doi: 10.4161/jkst.25666
Carroll CJ, Sayan BS, Bailey SG, McCormick J, Stephanou A, Latchman DS et al (2013) Regulation of myocardial interleukin-6 expression by p53 and STAT1. J Interferon Cytokine Res 33(9):542–548
pubmed: 23675777
doi: 10.1089/jir.2012.0165
Xu L, Zhang H, Wang Y, Yang A, Dong X, Gu L et al (2022) FABP4 activates the JAK2/STAT2 pathway via Rap1a in the homocysteine-induced macrophage inflammatory response in ApoE–/– mice atherosclerosis. Lab Invest 102(1):25–37
pubmed: 34725437
doi: 10.1038/s41374-021-00679-2
Jacoby JJ, Kalinowski A, Liu MG, Zhang SS, Gao Q, Chai GX et al (2003) Cardiomyocyte-restricted knockout of STAT3 results in higher sensitivity to inflammation, cardiac fibrosis, and heart failure with advanced age. Proc Natl Acad Sci USA 100(22):12929–12934
pubmed: 14566054
doi: 10.1073/pnas.2134694100
Haghikia A, Missol-Kolka E, Tsikas D, Venturini L, Brundiers S, Castoldi M et al (2011) Signal transducer and activator of transcription 3-mediated regulation of miR-199a-5p links cardiomyocyte and endothelial cell function in the heart: a key role for ubiquitin-conjugating enzymes. Eur Heart J 32(10):1287–1297
pubmed: 20965886
doi: 10.1093/eurheartj/ehq369
Podewski EK, Hilfiker-Kleiner D, Hilfiker A, Morawietz H, Lichtenberg A, Wollert KC et al (2003) Alterations in Janus kinase (JAK)-Signal transducers and activators of transcription (STAT) signaling in patients with end-stage dilated Cardiomyopathy. Circulation 107(6):798–802
pubmed: 12591746
doi: 10.1161/01.CIR.0000057545.82749.FF
Smith RM, Suleman N, Lacerda L, Opie LH, Akira S, Chien KR et al (2004) Genetic depletion of cardiac myocyte STAT-3 abolishes classical preconditioning. Cardiovascular Res 63(4):611–616
doi: 10.1016/j.cardiores.2004.06.019
Hattori R, Maulik N, Otani H, Zhu L, Cordis G, Engelman RM et al (2001) Role of STAT3 in ischemic preconditioning. J Mol Cell Cardiol 33(11):1929–1936
pubmed: 11708838
doi: 10.1006/jmcc.2001.1456
Bolli R, Stein AB, Guo Y, Wang OL, Rokosh G, Dawn B et al (2011) A murine model of inducible, cardiac-specific deletion of STAT3: its use to determine the role of STAT3 in the upregulation of cardioprotective proteins by ischemic preconditioning. J Mol Cell Cardiol 50(4):589–597
pubmed: 21223971
doi: 10.1016/j.yjmcc.2011.01.002
Boengler K, Hilfiker-Kleiner D, Heusch G, Schulz R (2010) Inhibition of permeability transition pore opening by mitochondrial STAT3 and its role in myocardial ischemia/reperfusion. Basic Res Cardiol 105(6):771–785
pubmed: 20960209
doi: 10.1007/s00395-010-0124-1
Zhang D, Wang F, Li P, Gao Y (2022) Mitochondrial Ca2 + homeostasis: emerging roles and clinical significance in Cardiac Remodeling. Int J Mol Sci [Internet]. 23(6)
Robichaux DJ, Harata M, Murphy E, Karch J (2023) Mitochondrial permeability transition pore-dependent necrosis. J Mol Cell Cardiol 174:47–55
pubmed: 36410526
doi: 10.1016/j.yjmcc.2022.11.003
Crow MT, Mani K, Nam Y-J, Kitsis RN (2004) The mitochondrial death pathway and Cardiac Myocyte apoptosis. Circul Res 95(10):957–970
doi: 10.1161/01.RES.0000148632.35500.d9
Kinnally KW, Peixoto PM, Ryu SY, Dejean LM (2011) Is mPTP the gatekeeper for necrosis, apoptosis, or both? Biochim Biophys Acta 1813(4):616–622
pubmed: 20888866
doi: 10.1016/j.bbamcr.2010.09.013
Comità S, Femmino S, Thairi C, Alloatti G, Boengler K, Pagliaro P et al (2021) Regulation of STAT3 and its role in cardioprotection by conditioning: focus on non-genomic roles targeting mitochondrial function. Basic Res Cardiol 116(1):56
pubmed: 34642818
doi: 10.1007/s00395-021-00898-0
Kelly R, King J, Lecour S (2008) Sphingosine-1-phosphate induced cardioprotection is mediated by STAT-3. J Mol Cell Cardiol 44(4):740–741
doi: 10.1016/j.yjmcc.2008.02.072
Knapp M (2011) Cardioprotective role of sphingosine-1-phosphate. J Physiol Pharmacology: Official J Pol Physiological Soc 62(6):601–607
Somers SJ, Frias M, Lacerda L, Opie LH, Lecour S (2012) Interplay between SAFE and RISK pathways in Sphingosine-1-Phosphate–Induced Cardioprotection. Cardiovasc Drugs Ther 26(3):227–237
pubmed: 22392184
doi: 10.1007/s10557-012-6376-2
Kelly RF, Lamont KT, Somers S, Hacking D, Lacerda L, Thomas P et al (2010) Ethanolamine is a novel STAT-3 dependent cardioprotective agent. Basic Res Cardiol 105(6):763–770
pubmed: 20938668
doi: 10.1007/s00395-010-0125-0
Deshpande GP, Imamdin A, Lecour S, Opie LH (2018) Sphingosine-1-phosphate (S1P) activates STAT3 to protect against de novo acute heart failure (AHF). Life Sci 196:127–132
pubmed: 29373815
doi: 10.1016/j.lfs.2018.01.023
Li J, Gao H, Huang J, Wang P, Huang Y, Luo W et al (2016) PKCζ interacts with STAT3 and promotes its activation in cardiomyocyte hypertrophy. J Pharmacol Sci 132(1):15–23
pubmed: 27094369
doi: 10.1016/j.jphs.2016.03.010
Jiang W, Xiong Y, Li X, Yang Y (2021) Cardiac Fibrosis: Cellular effectors, Molecular pathways, and exosomal roles. Front Cardiovasc Med. 8
Frangogiannis NG (2021) Cardiac fibrosis. Cardiovasc Res 117(6):1450–1488
pubmed: 33135058
doi: 10.1093/cvr/cvaa324
Hinderer S, Schenke-Layland K (2019) Cardiac fibrosis – a short review of causes and therapeutic strategies. Adv Drug Deliv Rev 146:77–82
pubmed: 31158407
doi: 10.1016/j.addr.2019.05.011
Zhang W, Qu X, Chen B, Snyder M, Wang M, Li B et al (2016) Critical roles of STAT3 in β-Adrenergic functions in the heart. Circulation 133(1):48–61
pubmed: 26628621
doi: 10.1161/CIRCULATIONAHA.115.017472
Tsai C-T, Lai L-P, Kuo K-T, Hwang J-J, Hsieh C-S, Hsu K-L et al (2008) Angiotensin II activates Signal Transducer and activators of transcription 3 via Rac1 in Atrial Myocytes and fibroblasts. Circulation 117(3):344–355
pubmed: 18172037
doi: 10.1161/CIRCULATIONAHA.107.695346
Yuan Y, Zhang Y, Han X, Li Y, Zhao X, Sheng L et al (2017) Relaxin alleviates TGFβ1-induced cardiac fibrosis via inhibition of Stat3-dependent autophagy. Biochem Biophys Res Commun 493(4):1601–1607
pubmed: 28942152
doi: 10.1016/j.bbrc.2017.09.110
Palomer X, Salvadó L, Barroso E, Vázquez-Carrera M (2013) An overview of the crosstalk between inflammatory processes and metabolic dysregulation during diabetic cardiomyopathy. Int J Cardiol 168(4):3160–3172
pubmed: 23932046
doi: 10.1016/j.ijcard.2013.07.150
Zhang Z, Zhou H, Zhou J (2021) Neuritin inhibits astrogliosis to ameliorate diabetic cognitive dysfunction. J Mol Endocrinol 66(4):259–272
pubmed: 33729996
doi: 10.1530/JME-20-0321
Gao H, Wu D, Zhang E, Liang T, Meng X, Chen L et al (2019) Phasic change and apoptosis regulation of JAK2/STAT3 pathway in a type 2 diabetic rat model. Am J Translational Res 11(2):911–930
Hu L, Ding M, Tang D, Gao E, Li C, Wang K et al (2019) Targeting mitochondrial dynamics by regulating Mfn2 for therapeutic intervention in diabetic cardiomyopathy. Theranostics 9(13):3687–3706
pubmed: 31281507
doi: 10.7150/thno.33684
Ding M, Liu C, Shi R, Yu M, Zeng K, Kang J et al (2020) Mitochondrial fusion promoter restores mitochondrial dynamics balance and ameliorates diabetic cardiomyopathy in an optic atrophy 1-dependent way. Acta Physiologica (Oxford England) 229(1):e13428
pubmed: 31840416
doi: 10.1111/apha.13428
Liu C, Han Y, Gu X, Li M, Du Y, Feng N et al (2021) Paeonol promotes Opa1-mediated mitochondrial fusion via activating the CK2α-Stat3 pathway in diabetic cardiomyopathy. Redox Biol 46:102098
pubmed: 34418601
doi: 10.1016/j.redox.2021.102098
Fu F, Liu C, Shi R, Li M, Zhang M, Du Y et al (2021) Punicalagin Protects against Diabetic Cardiomyopathy by promoting Opa1-Mediated mitochondrial Fusion via regulating PTP1B-Stat3 pathway. Antioxid Redox Signal 35(8):618–641
pubmed: 33906428
doi: 10.1089/ars.2020.8248
Wang L, Wu H, Deng Y, Zhang S, Wei Q, Yang Q et al (2021) FTZ Ameliorates Diabetic Cardiomyopathy by Inhibiting Inflammation and Cardiac Fibrosis in the Streptozotocin-Induced Model. Evidence-based complementary and alternative medicine: eCAM. 2021:5582567
He M, Li M, Guo Z (2022) STAT4 regulates cardiomyocyte apoptosis in rat models of diabetic cardiomyopathy. Acta Histochem 124(4):151872
pubmed: 35367814
doi: 10.1016/j.acthis.2022.151872
Pan A, Tan Y, Wang Z, Xu G (2019) STAT4 silencing underlies a novel inhibitory role of microRNA-141-3p in inflammation response of mice with experimental autoimmune myocarditis. Am J Physiol Heart Circ Physiol 317(3):H531–h40
pubmed: 31225989
doi: 10.1152/ajpheart.00048.2019
Taghavie-Moghadam PL, Gjurich BN, Jabeen R, Krishnamurthy P, Kaplan MH, Dobrian AD et al (2015) STAT4 deficiency reduces the development of atherosclerosis in mice. Atherosclerosis 243(1):169–178
pubmed: 26386214
doi: 10.1016/j.atherosclerosis.2015.08.045
Dobrian AD, Hatcher MA, Brotman JJ, Galkina EV, Taghavie-Moghadam P, Pei H et al (2015) STAT4 contributes to adipose tissue inflammation and atherosclerosis. J Endocrinol 227(1):13–24
pubmed: 26285907
doi: 10.1530/JOE-15-0098
Wang X, Ding X, Yan J, Lu Z, Cao H, Ni X et al (2021) STAT5 inhibitor attenuates atherosclerosis via inhibition of inflammation: the role of STAT5 in atherosclerosis. Am J Translational Res 13(3):1422–1431
Heusch G, Musiolik J, Kottenberg E, Peters J, Jakob H, Thielmann M (2012) STAT5 activation and cardioprotection by remote ischemic preconditioning in humans. Circ Res 110(1):111–115
pubmed: 22116817
doi: 10.1161/CIRCRESAHA.111.259556
Chen H, Jing X-Y, Shen Y-J, Wang T-L, Ou C, Lu S-F et al (2018) Stat5-dependent cardioprotection in late remote ischaemia preconditioning. Cardiovasc Res 114(5):679–689
pubmed: 29365089
doi: 10.1093/cvr/cvy014
Kimura A, Ishida Y, Furuta M, Nosaka M, Kuninaka Y, Kawaguchi M et al (2013) Pivotal involvement of IFN-gamma/Stat5 axis in compensatory cardiac hypertrophy induced by pressure overload. Eur Heart J. 34(suppl_1).
Nishimura Y, Nitto T, Inoue T, Node K (2008) STAT6 mediates apoptosis of human coronary arterial endothelial cells by Interleukin-13. Hypertens Res 31(3):535–541
pubmed: 18497474
doi: 10.1291/hypres.31.535
Khew-Goodall Y, Wadham C, Stein BN, Gamble JR, Vadas MA (1999) Stat6 activation is essential for interleukin-4 induction of P-selectin transcription in human umbilical vein endothelial cells. Arterioscler Thromb Vasc Biol 19(6):1421–1429
pubmed: 10364072
doi: 10.1161/01.ATV.19.6.1421
Peng H, Sarwar Z, Yang XP, Peterson EL, Xu J, Janic B Profibrotic Role for Interleukin-4 in Cardiac Remodeling and Dysfunction., Hypertension et al (1979) Dallas, Tex: 2015;66(3):582-9
Hikoso S, Yamaguchi O, Higuchi Y, Hirotani S, Takeda T, Kashiwase K et al (2004) Pressure overload induces cardiac dysfunction and dilation in signal transducer and activator of transcription 6-deficient mice. Circulation 110(17):2631–2637
pubmed: 15492321
doi: 10.1161/01.CIR.0000146798.70980.9A
Bao Q, Zhang B, Suo Y, Liu C, Yang Q, Zhang K et al (2020) Intermittent hypoxia mediated by TSP1 dependent on STAT3 induces cardiac fibroblast activation and cardiac fibrosis. eLife 9:e49923
pubmed: 31934850
doi: 10.7554/eLife.49923
Johnson AW, Kinzenbaw DA, Modrick ML, Faraci FM. Small-Molecule Inhibitors of Signal Transducer and Activator of Transcription 3 Protect Against Angiotensin II–Induced Vascular Dysfunction and Hypertension. Hypertension. 2013;61(2):437 − 42
Chen Q, Lv J, Yang W, Xu B, Wang Z, Yu Z et al (2019) Targeted inhibition of STAT3 as a potential treatment strategy for atherosclerosis. Theranostics 9(22):6424–6442
pubmed: 31588227
doi: 10.7150/thno.35528
Dutzmann J, Daniel J-M, Bauersachs J, Hilfiker-Kleiner D, Sedding DG (2015) Emerging translational approaches to target STAT3 signalling and its impact on vascular disease. Cardiovasc Res 106(3):365–374
pubmed: 25784694
doi: 10.1093/cvr/cvv103
Daniel JM, Dutzmann J, Bielenberg W, Widmer-Teske R, Gündüz D, Hamm CW et al (2012) Inhibition of STAT3 signaling prevents vascular smooth muscle cell proliferation and neointima formation. Basic Res Cardiol 107(3):261
pubmed: 22418922
doi: 10.1007/s00395-012-0261-9
Nakao S, Tsukamoto T, Ueyama T, Kawamura T (2020) STAT3 for Cardiac Regenerative Medicine: involvement in Stem Cell Biology, Pathophysiology, and Bioengineering. Int J Mol Sci. 21(6)
Scarabelli TM, Mariotto S, Abdel-Azeim S, Shoji K, Darra E, Stephanou A et al (2009) Targeting STAT1 by myricetin and delphinidin provides efficient protection of the heart from ischemia/reperfusion-induced injury. FEBS Lett 583(3):531–541
pubmed: 19116149
doi: 10.1016/j.febslet.2008.12.037
Townsend PA, Scarabelli TM, Pasini E, Gitti G, Menegazzi M, Suzuki H et al (2004) Epigallocatechin-3-gallate inhibits STAT-1 activation and protects cardiac myocytes from ischemia/reperfusion-induced apoptosis. FASEB J 18(13):1621–1623
pubmed: 15319365
doi: 10.1096/fj.04-1716fje